Search Videos and More
News
Dana-Farber Research Publication 12.15.2021
This twice-monthly newsletter highlights the research endeavors at Dana-Farber Cancer Institute, noting recently published papers available from PubMed where Dana-Farber faculty are listed as first or senior authors.
News
Dana-Farber Research Publication 12.1.2021
This twice-monthly newsletter highlights the research endeavors at Dana-Farber Cancer Institute, noting recently published papers available from PubMed where Dana-Farber faculty are listed as first or senior authors.
Video
Blood Cancer: Higher rates of precursor in high-risk individuals
Dr. Irene Ghobrial and Dr. Habib El-Khoury shared the first results from the Promise study, which screens individuals at high risk for multiple myeloma.
News
Implantable Device Helps Predict Drug Therapy Efficacy
Dana-Farber investigators recently launched a trial of a miniature device that can be implanted into ovarian tumors to deliver microdoses of different drugs, with the goal of rapidly measuring their effectiveness in killing cancer cells.
News
Dana-Farber Cancer Institute Faculty Among World’s Most Highly Cited Researchers
Dana-Farber Cancer Institute is proud to announce that 35 of its researchers have been named to the Highly Cited Researchers list of 2021 released today by the Institute for Scientific Information at Clarivate.
News
Papers Recount How Research Labs Learned to Work in Four-Part Harmony
A quartet of recent papers in the journal Clinical Cancer Research put the behind-the-scenes efforts involved in a major Moonshot project squarely on the record. The papers provide an inside look at some of the essential start-up activities of the Cancer Immune Monitoring and Analysis Centers and Cancer Immunologic Data Commons (CIMAC-CIDC), a network of laboratories and a bioinformatics center established to perform the analytic work involved in developing new immunotherapies for cancer.
News
Immunotherapy May Yield Longer Treatment-Free Survival than Targeted Therapy in Advanced Renal Cell Carcinoma Patients
Analysis uses novel endpoint of treatment-free survival (TFS) to ‘better balance the efficacy and toxicity to patients’